Characterization and Discovery of Genes Linked to Lipopolysaccharide in Lung Adenocarcinoma
-
By
-
Siding Zhou
-
Mingjun Gao
-
Shuangyong Dong
-
Mengmeng Wang
-
Hongbi Xiao
-
Yusheng Shu
-
Xiaolin Wang
-
December 3, 2025
-
Clinical Scorecard: Characterization and Discovery of Genes Linked to Lipopolysaccharide in Lung Adenocarcinoma
At a Glance
| Category | Detail |
|---|
| Condition | Lung Adenocarcinoma (LUAD) |
| Key Mechanisms | Aberrant expression of oncogenes and tumor suppressor genes, dysregulation of signaling pathways, and influence of intratumoral microbiota. |
| Target Population | Patients diagnosed with Lung Adenocarcinoma, particularly those with advanced stages. |
| Care Setting | Oncology clinics and research settings. |
Key Highlights
- LUAD accounts for over 50% of non-small cell lung cancer cases.
- LPS from different bacterial sources affects tumor behavior and immune response.
- Genes associated with lipopolysaccharide are significant prognostic indicators.
- ITGB4 gene shows high expression in LUAD and is linked to tumor progression.
- Microbial dysbiosis correlates with advanced disease and poor prognosis.
Guideline-Based Recommendations
Diagnosis
- Utilize mRNA expression and mutation data for accurate LUAD diagnosis.
Management
- Consider targeting genes associated with lipopolysaccharide for personalized treatment strategies.
Monitoring & Follow-up
- Monitor microbial composition in LUAD patients as a potential biomarker for disease progression.
Risks
- Increased risk of poor prognosis associated with reduced tumor microbial diversity.
Patient & Prescribing Data
Patients with Lung Adenocarcinoma, particularly those with EGFR mutations or KRAS mutations.
LPS influences therapeutic responses, particularly to PD-1/PD-L1 inhibitors.
Clinical Best Practices
- Integrate microbiome analysis into routine assessments for LUAD patients.
- Utilize prognostic models based on genes associated with lipopolysaccharide for treatment planning.
- Conduct further research on the role of ITGB4 in LUAD for potential therapeutic targeting.
Related Resources & Content